Serial cytogenetic (G banded) and FISH results
Months from diagnosis . | Karyotype . | FISH (%) . | Treatment . |
|---|---|---|---|
| 0 | 46,XY,t(1;9;22)(q32;q34;q11)[8] | D8Z1×3 (0) | Before treatment |
| 2 | 46,XY,t(1;9;22)(q32;q34;q11)[30] | — | Hydroxyurea |
| 4 | 46,XY,t(1;9;22)(q32;q34;q11)[30] | — | Imatinib |
| 7 | 46,XY,t(1;9;22)(q32;q34;q11)[20] | — | Imatinib |
| 9 | 46,XY,t(1;9;22)(q32;q34;q11)[11]/47,XY,+8[10] | — | Imatinib |
| 12 | 46,XY,t(1;9;22)(q32;q34;q11)[1]/47,XY,+8[16]/45,XY,−7[3] | — | Imatinib |
| 13 | — | Bcr/Abl+ (41) | Imatinib |
| 14 | 47,XY,+8[10] | Bcr/Abl+ (0) | Imatinib prior to BMT |
| 18 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (1) | None |
| 21 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (0) | None |
| 24 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (0) | None |
Months from diagnosis . | Karyotype . | FISH (%) . | Treatment . |
|---|---|---|---|
| 0 | 46,XY,t(1;9;22)(q32;q34;q11)[8] | D8Z1×3 (0) | Before treatment |
| 2 | 46,XY,t(1;9;22)(q32;q34;q11)[30] | — | Hydroxyurea |
| 4 | 46,XY,t(1;9;22)(q32;q34;q11)[30] | — | Imatinib |
| 7 | 46,XY,t(1;9;22)(q32;q34;q11)[20] | — | Imatinib |
| 9 | 46,XY,t(1;9;22)(q32;q34;q11)[11]/47,XY,+8[10] | — | Imatinib |
| 12 | 46,XY,t(1;9;22)(q32;q34;q11)[1]/47,XY,+8[16]/45,XY,−7[3] | — | Imatinib |
| 13 | — | Bcr/Abl+ (41) | Imatinib |
| 14 | 47,XY,+8[10] | Bcr/Abl+ (0) | Imatinib prior to BMT |
| 18 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (1) | None |
| 21 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (0) | None |
| 24 | 46,XY[30] | Bcr/Abl+ (0)/D8Z1×3 (0) | None |
—indicates not done; BMT, bone marrow transplantation.
Numbers of cells with each karyotype shown in square brackets. FISH results are given as percent of abnormal cells from 100 nuclei analyzed. Bcr-Abl and D8Z1 are the FISH probes used to detect t(9;22) and trisomy 8, respectively. All samples analyzed were bone marrow.